Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neuren Pharmaceuticals.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: Christmas rally runs out of puff, but market awaits crucial release from Neuren
Health & Biotech
ASX Health Stocks: HeraMed jumps 11pc on survey results, while Acrux seeks FDA approval for acne gel
News
ASX Capital Raise Roundup: TGIF (Thank God it’s FrIPOday)
News
Closing Bell: ASX closes the week 1.4pc higher, led by uranium
Health & Biotech
ScoPo’s Powerplays: Recent price swings uncovered hidden gems and buying opportunities in healthcare
Health & Biotech
ASX Health Stocks: Memphasys jumps on legal settlement after flaw with its Felix sperm-separating device
Health & Biotech
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Health & Biotech
ScoPo’s Powerplays: Smaller capped health stocks are still in ‘no man’s land’, but Neuren jumps 18pc this week
Health & Biotech
ASX health stocks: dorsaVi leads the pack with 12% jump on major contract extension
News
Market Highlights and 5 ASX Small Caps to watch on Thursday
Health & Biotech
ScoPo’s Powerplays: ASX biotech IPOs show ‘money is out there’; Virtus to benefit from rise in IVF
Health & Biotech
ScoPo’s Powerplays: Quarterlies to dictate price moves, as Nanosonics and Neuren come into play
Health & Biotech
The surge and plunge in ASX biotech shows what the FDA giveth, the FDA taketh away
News
ScoPo’s Powerplays: Mental health takes centre stage; Actinogen to progress Alzheimer’s study
Health & Biotech
These 3 ASX health stocks just took their next steps towards entering the USA
Health & Biotech
These ASX biotechs are on the verge of releasing Phase III clinical trial results
Experts
